Boehringer Ingelheim's IPF drug impresses despite non-significant data
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has published Phase II data for its tyrosine kinase inhibitor (TKI) BIBF 1120 showing a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF) but that failed to reach significance. Nevertheless, doctors remain optimistic about the drug, which in now under Phase III investigation.